Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVI-DROPS for Outpatient COVID-19
NCT05074394Phase 2Withdrawn
- Sponsor
- Sorrento Therapeutics
- Start
- Nov 2021
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of STI-2099 in coronavirus disease 2019 (COVID-19), sponsored by Sorrento Therapeutics. Planned start Nov 2021; status: withdrawn.
02
Drugs
STI-2099
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05074394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05074394.